Meylan Cepeda
Overview
Explore the profile of Meylan Cepeda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lorenzo G, Ortiz R, Mendez R, Rodriguez M, Marrero R, de la Barca N, et al.
BJGP Open
. 2022 Apr;
6(3).
PMID: 35379687
Background: The Center of Molecular Immunology of Cuba has developed a programme for the conducting of multicentre oncology clinical trials in primary healthcare centres since 2009. Aim: To evaluate the...
2.
Filgueira L, Cervantes J, Lovelle O, Herrera C, Figueredo C, Caballero J, et al.
Immunotherapy
. 2021 Jan;
13(4):289-295.
PMID: 33397150
In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody...
3.
Caballero A, Filgueira L, Betancourt J, Sanchez N, Hidalgo C, Ramirez A, et al.
Clin Transl Immunology
. 2020 Dec;
9(11):e1218.
PMID: 33304584
Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T-cell activation. Itolizumab is a humanised...
4.
Saavedra D, Ane-Kouri A, Sanchez N, Filgueira L, Betancourt J, Herrera C, et al.
Immun Ageing
. 2020 Dec;
17(1):34.
PMID: 33292350
Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the world has been placed. In Cuba, the first case of COVID-19 was reported on March 11. Elderly...
5.
Diaz Y, Ramos-Suzarte M, Martin Y, Calderon N, Santiago W, Vinet O, et al.
Gerontology
. 2020 Oct;
66(6):553-561.
PMID: 33105142
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11, 2020....
6.
de la Torre A, Perez K, Vega A, Santiesteban E, Ruiz R, Hernandez L, et al.
Breast Cancer (Auckl)
. 2016 Feb;
10:5-11.
PMID: 26917965
NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vaccine, consisting in very small-sized proteoliposomes (VSSP) obtained by the incorporation of NGcGM3 into the outer membrane...
7.
Alfonso S, Valdes-Zayas A, Santiesteban E, Flores Y, Areces F, Hernandez M, et al.
Clin Cancer Res
. 2014 May;
20(14):3660-71.
PMID: 24788102
Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of efficacy and safety of racotumomab as switch maintenance...
8.
Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, et al.
Cancer Manag Res
. 2012 Oct;
4:341-5.
PMID: 23055778
NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target for cancer immunotherapy because they are minimally or not expressed in normal human tissues. Melanoma patients treated...
9.
de la Torre A, Hernandez J, Ortiz R, Cepeda M, Perez K, Car A, et al.
Breast Cancer (Auckl)
. 2012 Oct;
6:151-7.
PMID: 23055739
Patients treated with vaccines based on NGlycolil gangliosides have showed benefit in progression free survival and overall survival. These molecules, which have been observed in breast cancer cells, are minimally...